Treatment advances in head and neck cancer
Treatment choices based on risk factors in locally advanced head and neck cancers were considered in an educational session at Congress 2012
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Treatment choices based on risk factors in locally advanced head and neck cancers were considered in an educational session at Congress 2012
Daily Editorial by Matthias Preusser, Associate Editor of the ESMO Congress Daily - Sunday 30 September 2012
Findings from an international survey presented in the Special Session on Saturday morning at ESMO 2012 concluded that hundreds of millions of cancer patients around the world are suffering needlessly due to government failures to ensure adequate access to pain-relieving drugs.
Joint ESMO-ESTRO symposium explored innovative approaches to the treatment of brain metastases, including prevention in patients with primary cancers, treating patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC) and brain metastases with the combination of lapatinib and capecitabine, and the potential for radiation dose escalation.
Crizotinib superior to pemetrexed or docetaxel in the first head-to-head comparison study
Lurbinectedin is now being evaluated against comparator therapy with topotecan
An educational session held yesterday, which focused on the the diagnosis and management of advanced melanoma, revealed the extraordinary progress made in the past few years.
Extensive efforts are currently underway to define biological markers as the basis for treatment selection for patients with glioblastomas, delegates heard in an ESMO 2012 symposium dedicated to exploring new avenues in molecular neuro-oncology diagnosis and treatment.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.